POSB19 Matching-Adjusted Indirect Comparison of Trastuzumab Deruxtecan vs. Eribulin, Capecitabine, and Vinorelbine for Treating Human Epidermal Growth Factor Receptor 2-Positive Unresectable or Metastatic Breast Cancer after Two or More Anti-Human Epidermal Growth Factor Receptor 2-Positive Therapies
作者
K. Dunton,Gerard T. Vondeling,A Paine
出处
期刊:Value in Health [Elsevier BV] 日期:2022-01-01卷期号:25 (1): S28-S28被引量:1